ストックスクリーナーアプリを入手
2.26
0.44%
0.010
アフターアワーズ：
2.25
-0.010
-0.44%
前日終値:
$2.25
開ける：
$2.25
24時間の取引高:
116.69K
Relative Volume:
0.78
時価総額：
$22.55M
収益：
-
当期純損益:
$-37.64M
株価収益率:
-0.5172
EPS:
-4.3698
ネットキャッシュフロー:
$-33.40M
1週間 パフォーマンス:
-4.64%
1か月 パフォーマンス:
-11.02%
6か月 パフォーマンス:
-57.60%
1年 パフォーマンス:
-81.87%
1日の値動き範囲:
$2.25
$2.43
1週間の範囲:
$2.22
$2.48
52週間の値動き範囲:
$1.70
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
名前
Atossa Therapeutics Inc
セクター
電話
206.588.0256
住所
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.26 | 25.05M | 0 | -37.64M | -33.40M | -4.3698 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-01-26 | 開始されました | Maxim Group | Buy |
Atossa Therapeutics Inc (ATOS) 最新ニュース
Debt to equity ratio of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBITDA forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Enterprise value to EBIT forward of Atossa Therapeutics, Inc. – HAM:YAG - TradingView
Atossa Therapeutics (ATOS) Holds Steady at $2.52 — Awaiting Catalyst Within $2.39–$2.65 RangeTPO Profile - siam.in
Atossa Therapeutics explores collaborative clinical research for (Z)-endoxifen applications - Traders Union
Atossa (ATOS) Results Breakdown: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Share Response: Shares Rise 2.76% at the CloseEarnings Power Value - vinanet.vn
Atossa Therapeutics advances investigational Z-endoxifen research for broader DMD applications - Traders Union
We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - Sahm
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
ATOS: Multiple Catalysts Converge in 2H26 - Smartkarma
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Atossa Therapeutics pursues ESR1 mutation research to tackle endocrine resistance in breast cancer - Traders Union
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Atossa Therapeutics shifts clinical focus to pre-surgical breast cancer patients - Traders Union
Atossa Therapeutics (ATOS) Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock SlipsQuarterly Profit Report - dars.gov.et
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Atossa Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Weekly Recap: Q2 net loss, financing and (Z)-endoxifen Phase 2 progress - TradingView
Atossa Therapeutics reports Q2 2026 results, ad... - Pluang
Atossa Therapeutics (ATOS) Dips 2.48% to $2.36 as Stock Tests Key Support ZoneWyckoff Upthrust - dars.gov.et
Atossa Therapeutics Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Atossa Therapeutics investigates (Z)-endoxifen for McCune-Albright syndrome and endocrine disorders - tradersunion.com
Atossa Therapeutics (ATOS) Advances Clinical Pipeline Amid Valua - GuruFocus
Form 8K Atossa Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
Atossa Therapeutics Q2 net loss widens on lower interest income - TradingView
Atossa Therapeutics reports Q2 2026 net loss $8.5M, cash $26.1M; advances (Z)-endoxifen programs - TradingView
ATOS: Q2 2026 net loss was $8.5M; (Z)-endoxifen programs advanced and $4.5M in new capital raised - TradingView
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
ATOSSA THERAPEUTICS, INC. Q2 2026: Net loss $(8.49M), EPS $(0.95) — 10-Q Summary - TradingView
Atossa Therapeutics (NASDAQ: ATOS) posts $18.1M loss, flags going concern risk - Stock Titan
Atossa Therapeutics strengthens pipeline with new data on Z-endoxifen breast cancer therapy - tradersunion.com
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Atossa Therapeutics advances rare disease pipeline with (Z)-endoxifen strategy - Traders Union
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Narrows Loss Despite No Revenue; Stock Down 5.48%Financial Health Score - vinanet.vn
Atossa Therapeutics advances biomarker-driven Z-endoxifen treatment for breast cancer - Traders Union
Atossa Therapeutics (ATOS) Focuses on Execution Amid Challenging Valuation and Mixed Guru Interest - GuruFocus
Atossa study shows preclinical activity in breast cancer models By Investing.com - Investing.com South Africa
Atossa Therapeutics (ATOS) Unveils Promising Preclinical Breast Cancer Study Amidst Challenging Valuation - GuruFocus
Atossa study shows preclinical activity in breast cancer models - Investing.com
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer - Morningstar
Five New Compounds Show Activity in Breast Cancer Models With ESR1 Mutations - Stock Titan
Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atossa Therapeutics (ATOS) Gains 4.6%: Biotech Stock Tests Key ResistanceTriple EMA - vinanet.vn
TradingKey - TradingKey
Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ATOS Q1 2026 Earnings: EPS Surprise of 82.23% Amidst Pre-Revenue StageQuarterly Earnings - vinanet.vn
Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
ATOS|Atossa Therapeutics Inc|Price:2.295|Chg%:-0.115 - TradingKey
ATOSSA THERAPEUTICS, INC. advances omics and organoid research in rare cancer field - Traders Union
Atossa Therapeutics Inc (ATOS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.15%
大文字化:
|
ボリューム (24 時間):